Mortality Risk Conferred by Small Elevations of Creatine Kinase-MB Isoenzyme After Percutaneous Coronary Intervention
|
|
- Rafe Baker
- 5 years ago
- Views:
Transcription
1 Journal of the American College of Cardiology Vol. 42, No. 8, by the American College of Cardiology Foundation ISSN /03/$30.00 Published by Elsevier Inc. doi: /s (03) Mortality Risk Conferred by Small Elevations of Creatine Kinase-MB Isoenzyme After Percutaneous Coronary Intervention Interventional Cardiology John P. A. Ioannidis, MD,* Evangelia Karvouni, MD, Demosthenes G. Katritsis, MD, PHD, FACC Ioannina and Athens, Greece; and Boston, Massachusetts OBJECTIVES BACKGROUND METHODS RESULTS CONCLUSIONS The aim of this study was to assess whether small creatine kinase-mb isoenzyme (CK-MB) elevations after percutaneous coronary intervention (PCI) affect the subsequent mortality risk. Several studies have evaluated the relationship of CK-MB levels after PCI with the subsequent risk of death. While there is consensus that elevations exceeding 5 times the upper limit of normal increase mortality significantly, there is uncertainty about the exact clinical impact of smaller CK-MB elevations. We performed a meta-analysis of seven studies with CK-MB measurements and survival outcomes on 23,230 subjects who underwent PCI. Data were combined with random effects models. Mean follow-up was 6 to 34 months per study. By random effects, 19% (95% confidence interval [CI], 16% to 23%) had one- to five-fold CK-MB elevations, while only 6% (95% CI, 5% to 9%) had 5-fold elevations. Compared with subjects with normal CK-MB, there was a dose-response relationship with relative risks for death being 1.5 (95% CI, 1.2 to 1.8, no between-study heterogeneity) with one- to three-fold CK-MB elevations, 1.8 (95% CI, 1.4 to 2.4, no between-study heterogeneity) with three- to five-fold CK-MB elevations, and 3.1 (95% CI, 2.3 to 4.2, borderline between-study heterogeneity) with over five-fold CK-MB elevations (p for all). Any increase in CK-MB after PCI is associated with a small, but statistically and clinically significant, increase in the subsequent risk of death. (J Am Coll Cardiol 2003;42: ) 2003 by the American College of Cardiology Foundation Microvascular coronary embolization, either spontaneous or iatrogenic, is now a well-recognized clinical entity (1). Creatine kinase-mb isoenzyme (CK-MB) elevation is common after percutaneous coronary intervention (PCI) and, if sought, can be detected in up to 25% of cases (2) or even a larger percentage if more sensitive markers, such as troponin T or I, are used (3,4). Extensive cardiac enzyme See page 1412 release after PCI has been correlated with late mortality in several studies (5,6). Still, however, the amount of increase that is clinically relevant and the threshold level of CK-MB that has prognostic significance remain elusive (7). Post- PCI CK-MB isoenzyme increases up to 5 times the upper limit of normal have typically not been found to be statistically significant for predicting survival, and their clinical meaning has been questioned (7,8). Nevertheless, the majority of post-pci CK-MB elevations are in this From the *Clinical Trials and Evidence-Based Medicine Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine and the Biomedical Research Institute, Foundation for Research and Technology, Hellas Ioannina, Greece; the Division of Clinical Care Research, Tufts-New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts; and the Department of Cardiology, Athens Euroclinic, Athens, Greece. Manuscript received February 26, 2003; revised manuscript received April 4, 2003, accepted April 10, range; most are actually in the range of 1 to 3 times the upper limit of normal (5). Previous studies have had inadequate power to evaluate the exact impact of such enzyme elevations on the subsequent risk of death. Thus, we performed a comprehensive meta-analysis of all pertinent studies to clarify the clinical significance of small CK-MB elevations after PCI. METHODS Eligibility and search strategy. The meta-analysis included studies reporting data on post-pci CK-MB values in relationship to the subsequent risk of death during follow-up. Abstracts were not eligible. All types of PCI were eligible including percutaneous transluminal coronary angioplasty (PTCA), stent placement, atherectomy (directional, rotational, extraction), and excimer laser. Whenever study reports included both patients with and without PCI, only the first group was used. The meta-analysis focused on the strata of one- to three-fold elevation and three- to five-fold elevation compared with normal CK-MB, but also examined data on subjects with over five-fold CK-MB elevations to address whether there is a clear dose-response relationship. Because it is unclear whether the potential prognostic effect of CK-MB elevations may change in the very long-term due to competing causes of death or may be affected by extensive missing information and censoring, we
2 JACC Vol. 42, No. 8, 2003 October 15, 2003: Ioannidis et al. Small CK-MB Elevations Post-PCI 1407 Abbreviations and Acronyms CI confidence interval CK-MB creatine kinase-mb isoenzyme EPIC Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications trial EPILOG Evaluation in PTCA to Improve Longterm Outcome with Abciximab Glycoprotein IIb/IIIa Blockade trial IMPACT-II Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II study PCI percutaneous coronary intervention PTCA percutaneous transluminal coronary angioplasty focused on studies with mean follow-up between three months and three years; whenever reports with different follow-up were available from the same study, we selected the data closest to six months. We excluded studies with CK data without additional information on deaths according to MB isoenzyme strata. Potentially eligible studies were carefully scrutinized for overlap of subjects. Reports providing information on a subgroup of a larger population described in another report were excluded, while, in cases of considerable partial overlap of subjects between reports, we generally retained only the largest study with available data to avoid double counting. We identified eligible studies in MEDLINE and EM- BASE (last search updated February 2003) using the keywords creatine kinase AND angioplasty or stent. We also screened bibliographies of retrieved studies and communicated with experts. Data. For each study we recorded study design, the types of PCI employed, and the number of subjects in CK-MB strata (normal, 1- to 3-fold elevation, 3- to 5-fold elevation, 5-fold elevation). The outcome of interest was mortality during the available follow-up, excluding acute events during the PCI. Deaths were recorded per stratum. Whenever exact numbers were not provided, we approximated risk ratios and 95% confidence intervals (CI) from Kaplan- Meier curves and other presented information. Two independent investigators extracted data, and discrepancies were resolved with consensus. Analysis. Proportions of the subjects in each CK-MB stratum across studies were synthesized with random effects models. We evaluated separately the risk ratio for mortality with one- to five-fold, one- to three-fold, three- to fivefold, and 5-fold elevation versus normal CK-MB. Risk ratios for mortality were estimated in each study, and between-study heterogeneity was estimated using the Q statistic (significant for p 0.10) (9). Risk ratios were then combined using the general variance method, weighting each log-transformed risk ratio by the inverse of its variance (fixed effects model) or by the inverse of the sum of its variance plus the between-study variance (random effects model) (9). In the absence of between-study heterogeneity, the two models coincide, while random effects are more appropriate when there is between-study heterogeneity. Absolute risk differences for mortality across different CK-MB strata were calculated by multiplying the random effects relative risk increase (risk ratio 1) times the observed death rates in the stratum of subjects with normal CK-MB after PCI. Typical observed death rates were based on Kaplan-Meier estimates at one and two years of follow-up in studies that provided such information. Analyses were conducted in SPSS 10.0 (SPSS Inc., Chicago, Illinois) and in Meta-Analyst (Joseph Lau, Boston, Massachusetts). The p values are two-tailed. RESULTS Eligible studies. We identified 23 potentially eligible reports (5,6,8,10 29). Fifteen were excluded up front (CKbased strata [n 4] [15 18]; entirely included in larger studies [n 6] [19 24]; partial overlap with other larger studies with available data [n 5] [25 29]). Another large study (8) provided neither separate information for all the pertinent CK-MB strata nor absolute numbers of deaths, and it largely overlapped with another study that provided detailed pertinent data for the meta-analysis. We were unable to obtain additional clarifications from the primary Table 1. Characteristics of Included Studies Study (yr) n* Age (yrs) Male (%) Procedures Involved (% of Total Number) Reported Protocol for Obtaining CK-MB Measurements Brener (2002) 3, (mean) 71 Various (not specified) At 8 h, next morning and with suspected ischemia Akkerhuis (2002) 8, (median) 69 PTCA (81%), stent (8%), DCA (6%), Variable, used peak value within 48 h other (5%) Stone (2001) 7, (mean) 70 Stent (37%), atheroablation (37%), both (17%), PTCA (9%) At baseline, 8 12 and h; if abnormal, also every 8 12 h until normalized Kini (1999) 1, (mean) 68 Stent (29%), HRSA (25%), both At baseline, 6 8 and h (32%), PTCA (10%), other (4%) Baim (1998) (mean) 79 DCA (50%), PTCA (50%) At baseline, 4 6 h, and hospital discharge or 24 h Harrington (1995) 483 no data no data DCA (58%), PTCA (42%) At 12 and 24 h and with suspected ischemia Kugelmass (1994) (mean) 82 Stent (51%), DCA (49%) At baseline and 24 h; if abnormal, repeated until peak *With available CK-MB data; composite data from five trials (PURSUIT, IMPACT-II, EPIC, EPILOG, CAPTURE). CK-MB creatine kinase-mb isoenzyme; DCA directional coronary atherectomy; HSRA high-speed rotational atherectomy; PTCA percutaneous transluminal coronary angioplasty.
3 1408 Ioannidis et al. JACC Vol. 42, No. 8, 2003 Small CK-MB Elevations Post-PCI October 15, 2003: Table 2. Distribution of CK-MB Values and Follow-Up Study (yr) Percent With Death Rate CK-MB Increase Mean (Normal CK-MB) Follow-Up None >5 (months) 1 Year (%)* 2 Years (%)* Brener (2002) Akkerhuis (2002) ND ND Stone (2001) Kini (1999) ND ND Baim (1998) ND ND Harrington (1995) ND ND Kugelmass (1994) *Estimated risk of death based on Kaplan-Meier plots for patients who had normal CK-MB after percutaneous coronary intervention; composite data from five trials (PURSUIT, IMPACT-II, EPIC, EPILOG, CAPTURE); subjects with up to two-fold elevation are included in the None category. CK-MB creatine kinase-mb isoenzyme; ND no data available. investigators. Nevertheless, this study was included in a sensitivity analysis for the comparison of one- to five-fold CK-MB elevation versus normal controls. The seven eligible studies with complete pertinent data (5,6,10 14) totaled 23,230 subjects (Table 1). Four of the eligible studies clearly stated that they excluded patients with major complications during catheterization (6,10,11,13), while three studies (5,12,14) did not comment on whether any such patients were included. All studies included a preponderance of males with a mean or median age between 58 to 65 years. A variety of PCI types had been employed in each study (Table 1). The protocol for measuring CK-MB in each study is shown in Table 1. The seven eligible studies included 16,133 subjects with normal CK-MB, 3,981 subjects with one- to three-fold, 1,124 subjects with three- to five-fold, and 1,992 subjects with over five-fold CK-MB elevations (Table 2). The percentage of subjects with one- to five-fold CK-MB elevation (range, 8.6% to 27.7%) exceeded the percentage of subjects with larger CK-MB elevations (range, 2.4% to 11.8%) across all studies. By random effects, the overall percentage was 19% (95% CI, 16% to 23%) for one- to five-fold CK-MB elevations versus 6% (95% CI, 5% to 9%) for CK-MB elevations exceeding five-fold the upper limit of normal. Meta-analysis. There was no significant between-study heterogeneity in the risk ratio estimates in any of the contrasts of CK-MB strata (p 0.10), with the exception of the comparison between subjects with over five-fold CK-MB elevations against subjects with normal CK-MB where borderline between-study heterogeneity was seen (p 0.10). One- to five-fold CK-MB elevations conferred a significant increase in the risk of mortality with an overall risk ratio of 1.5 (95% CI, 1.3 to 1.8, p 0.001; Fig. 1A). There was a dose-response: the summary risk ratio was 1.5 for one- to three-fold elevation (95% CI, 1.2 to 1.8, p 0.001; Fig. 1B) and 1.8 for three- to five-fold elevation (95% CI, 1.4 to 2.4, p 0.001; Fig. 1C). Fixed and random effects coincided, and the results were very consistent across studies. The dose-response was also clear when subjects with over five-fold CK-MB were considered. Their risk ratio compared with normal CK-MB subjects was 3.1 (95% CI, 2.3 to 4.2, p 0.001) by random effects calculations (Fig. 1D). There was a suggestion that for this contrast the risk ratio estimates tended to be higher in three (5,10,12) of the four (5,10,12,14) studies with relatively shorter follow-up. A sensitivity analysis including Ellis et al. (8) in the oneto five-fold versus normal CK-MB analysis yielded similar results (summary risk ratio 1.6, 95% CI, 1.3 to 1.8, p 0.001). There was no significant difference in the risk ratio estimates of small versus larger studies or in early published versus recent studies in any of the considered contrasts (not shown). Based on Kaplan-Meier plots, the one-year and two-year mortality risks among patients with normal CK-MB was 3% to 4% and 6% to 8%, respectively, in studies that provided such data (Table 2). For a cohort with a death rate of 3.5% per year among subjects with normal CK-MB, the absolute increase in the mortality risk among patients with one- to three-fold, three- to five-fold, and 5-fold CK-MB elevations after PCI would be 1.7%, 2.8%, and 7.4% per year, respectively. DISCUSSION This meta-analysis based on data from over 23,000 subjects clarifies the clinical significance of small CK-MB elevations after PCI. Any CK-MB increase is associated with a potential increase in the subsequent risk of death during follow-up. One- to three-fold CK-MB elevations increase the risk of death by approximately 50%. In a step-wise fashion, the risk is increased by 80% with three- to five-fold CK-MB elevations and is tripled with over five-fold CK-MB elevations. Prior investigations had clearly stressed the adverse prognosis of subjects with CK-MB increases exceeding 5 times (or even 8 times) the upper limit of normal (6,8). However, such CK-MB elevations are on average three times less frequent than elevations in the one- to five-fold range. Thus, the impact of small CK-MB elevations on excess mortality on a population basis is not negligible when
4 JACC Vol. 42, No. 8, 2003 October 15, 2003: Ioannidis et al. Small CK-MB Elevations Post-PCI 1409 Figure 1. Relative risk of death with various creatine kinase-mb isoenzyme (CK-MB) elevations. Each study is shown by the risk ratio estimate and the corresponding 95% confidence interval. Also shown is the summary estimate for all studies. (A) One- to five-fold elevation versus normal CK-MB. (B) Three- to five-fold elevation versus normal CK-MB. (C) Three- to five-fold elevation versus normal CK-MB. (D) 5-fold elevation versus normal CK-MB. compared against the impact of the more unusual high-level increases. Approximately one in five subjects undergoing PCI will have an elevation of CK-MB by one- to five-fold, and one in 15 subjects will have an even larger increase. Stent and atheroablative procedures may confer a higher risk of CK-MB release than PTCA (10,12,13), and combined procedures may increase the risk even further (6). Saphenous vein graft interventions may also have a higher risk of CK-MB release (27). In certain clinical settings, such as diabetes mellitus and states of elevated C-reactive protein or other inflammatory markers, patients are particularly prone to coronary microembolization, either spontaneous or iatrogenic (1). We could not address separately the risk of death in these subgroups according to CK-MB strata. However, it is possible that the absolute excess mortality may be even larger in high-risk subpopulations. We should acknowledge that the studies included in the meta-analysis used a considerable variety of revascularization procedures. Even with 23,000 patients, the metaanalysis is not fully powered to examine whether there are any differences on what subclinical CK-MB elevations mean for different types of PCI. However, the absence of between-study heterogeneity in the risk ratios suggests that any such differences, if present, may not be very prominent. Another issue is whether the impact of the CK-MB elevations on mortality risk remains constant over long durations of follow-up. This seems to be the case at least for two to three years with minor CK-MB elevations; CK-MB may be an index of myocardial damage that carries prognostic information in the long-term even with small increases. For high CK-MB elevations, other investigators have noted a more prominent adverse prognostic impact in the early months after PCI (6), and our data, although not definitive, are also consistent with this perspective. Finally, it would be interesting to evaluate also with large-scale studies the ability of other myocardial enzymes (3,4) to predict long-term outcomes after PCI. It has been speculated whether periprocedural embolization carries the exact same adverse prognostic implications as with spontaneous myocardial necrosis (5). Other investigators observed two- to 2.5-fold increases in the risk of death with one- to five-fold CK-MB elevations after spontaneous infarction and suggested that iatrogenic and spontaneous CK-MB elevations may have similar implications (5). Although our risk ratio estimates are somewhat smaller,
5 1410 Ioannidis et al. JACC Vol. 42, No. 8, 2003 Small CK-MB Elevations Post-PCI October 15, 2003: and the CIs exclude a doubling in mortality risk with oneto five-fold CK-MB elevations, any enzyme release post- PCI does seem to affect prognosis. The level of post-pci CK-MB elevation that carries an adverse prognosis has been debated (7). Based on our findings and in concordance with the recent redefinition criteria of myocardial infarction (30), we conclude that any increase in CK-MB post-pci is associated with a small, but significant, increase in the subsequent risk of death. Given that minor elevations are far more common than more pronounced CK-MB increases, their mortality impact may be considerable in the population of patients undergoing PCI. We should acknowledge that our meta-analysis focuses on the importance of mostly asymptomatic elevations of CK-MB after PCI as contrasted to major symptomatic periprocedural myocardial infarctions. We have clearly documented an increasing long-term mortality risk with increasing levels of CK-MB elevation. Nevertheless, this risk would have to be weighted against the anticipated benefitof the PCI and should not lead to abandoning PCI, when this is clearly indicated. For example, the risk conferred from small CK-MB elevations may be negligible compared with the benefit obtained from revascularization in a patient with tight proximal left anterior descending stenosis with unstable angina and a positive stress test. Risks and benefits should be carefully weighted in each case. Moreover, we should caution that the observed association between CK-MB elevation and subsequent mortality risk does not necessarily prove causality for this relationship. The CK-MB elevation may indeed reflect direct myocardial damage in some cases. However, in other cases it may simply be a surrogate for more extensive disease or more vulnerable plaques, and the subsequent increased mortality may not be directly linked to the original PCI-related microinfarction. New strategies should be considered to try to minimize the risk of cardiac events and death after PCI. For example, use of platelet glycoprotein IIb/IIIa receptor antagonists has recently been shown to decrease the risk of death both in the short- and long-term in patients undergoing PCI (31). Reprint requests and correspondence: Dr. John P. A. Ioannidis, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina 45110, Greece. jioannid@ cc.uoi.gr. REFERENCES 1. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000;101: Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31: Johansen O, Brekke M, Stromme JH, et al. Myocardial damage during percutaneous transluminal coronary angioplasty as evidenced by troponin T measurements. Eur Heart J 1998;19: Bonz AW, Lengenfelder B, Strotmann J, et al. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). J Am Coll Cardiol 2002; 21:40 : Akkerhuis KM, Alexander JH, Tardiff BE, et al. Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different? Circulation 2002;105: Stone GW, Mehran R, Dangas G, et al. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. Circulation 2001;104: Colombo A, Stankovic G. Nothing is lower than 0, and 3 is closer to 0 than to 5 medicine is not arithmetic. Eur Heart J 2002;23: Ellis SG, Chew D, Chan A, et al. Death following creatine kinase-mb elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-mb level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation 2002;106: Pettiti D. Meta-Analysis, Decision Analysis and Cost-Effectiveness Analysis. 2nd edition. New York, NY: Oxford University Press, Kini A, Kini S, Marmur JD, et al. Incidence and mechanism of creatine kinase-mb enzyme elevation after coronary intervention with different devices. Catheter Cardiovasc Intervent 1999;48: Brener SJ, Lytle BW, Schneider JP, Ellis SG, Topol EJ. Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. J Am Coll Cardiol 2002;40: Harrington RA, Lincoff AM, Califf RM, et al. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). J Am Coll Cardiol 1995;25: Kugelmass AD, Cohen DJ, Moscucci M, et al. Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. Am J Cardiol 1994;74: Baim DS, Cutlip DE, Sharma SK, et al. Final results of the Balloon vs Optimal Atherectomy Trial (BOAT). Circulation 1998;97: Kong TQ, Davidson CJ, Meyers SN, Tauke JT, Parker MA, Bonow RO. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA 1997;277: Abdelmeguid AE, Ellis SG, Sapp SK, Whitlow PL, Topol EJ. Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. Am Heart J 1996;131: Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-mb fraction after percutaneous coronary interventions. Circulation 1996;94: Abdelmeguid AE, Whitlow PL, Sapp SK, Ellis SG, Topol EJ. Long-term outcome of transient, uncomplicated in-laboratory coronary artery closure. Circulation 1995;91: Saucedo JF, Mehran R, Dangas G, et al. Long-term clinical events following creatine kinase-myocardial band isoenzyme elevation after successful coronary stenting. J Am Coll Cardiol 2000;35: Tardiff BE, Califf RM, Tcheng JE, et al. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention: IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. J Am Coll Cardiol 1999;33: Simoons ML, van den Brand M, Lincoff M, et al. Minimal myocardial damage during coronary intervention is associated with impaired outcome. Eur Heart J 1999;20: Gruberg L, Mehran R, Waksman R, et al. Creatine kinase-mb fraction elevation after percutaneous coronary intervention in patients with chronic renal failure. Am J Cardiol 2001;87: Fuchs S, Kornowski R, Mehran R, et al. Prognostic value of cardiac troponin-i levels following catheter-based coronary interventions. Am J Cardiol 2000;85: Dangas G, Mehran R, Feldman D, et al. Postprocedure creatine kinase-mb elevation and baseline left ventricular dysfunction predict one-year mortality after percutaneous coronary intervention. Am J Cardiol 2002;89: Lincoff AM, Tcheng JE, Califf RM, et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/ IIIa blockade with abciximab: one-year outcome in the EPILOG trial:
6 JACC Vol. 42, No. 8, 2003 October 15, 2003: Ioannidis et al. Small CK-MB Elevations Post-PCI 1411 Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation 1999;99: Narins CR, Miller DP, Califf RM, Topol EJ. The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial: Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. J Am Coll Cardiol 1999;33: Hong MK, Mehran R, Dangas G, et al. Creatine kinase-mb enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. Circulation 1999;100: Jeremias A, Albirini A, Ziada KM, et al. Prognostic significance of creatine kinase-mb elevation after percutaneous coronary intervention in patients with chronic renal dysfunction. Am Heart J 2002;143: Brener SJ, Ellis SG, Schneider J, Topol EJ. Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J 2002;23: Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36: Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 2003;41:26 32.
Journal of the American College of Cardiology Vol. 38, No. 3, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 38, No. 3, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01423-1 Effect
More informationClinical Outcomes After Detection of Elevated Cardiac Enzymes in Patients Undergoing Percutaneous Intervention
88 JACC Vol. 33, No. 1 Clinical Outcomes After Detection of Elevated Cardiac Enzymes in Patients Undergoing Percutaneous Intervention BARBARA E. TARDIFF, MD, ROBERT M. CALIFF, MD, FACC, JAMES E. TCHENG,
More informationMyocardial Damage in Successful Single Vessel Coronary Angioplasty as Assessed by Creatinine Kinase and its Myocardium Band Isoenzyme Levels
ORIGINAL ARTICLE Myocardial Damage in Successful Single Vessel Coronary Angioplasty as Assessed by Creatinine Kinase and its Myocardium Band Isoenzyme Levels Shahid Abbas, Farhan Tayyab, Naseer Ahmed Samor,
More informationCreatine kinase-mb elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes
European Heart Journal (2004) 25, 313 321 Clinical research Creatine kinase-mb elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes M.T.
More informationHeart Online First, published on December 30, 2005 as /hrt
Heart Online First, published on December 30, 2005 as 10.1136/hrt.2005.078758 Attributable risk of clinical endpoints Clinical endpoint definitions following percutaneous coronary intervention and their
More informationClinical Investigations
Clinical Investigations Risk Factors of Cardiac Troponin T Elevation in Patients with Stable Coronary Artery Disease After Elective Coronary Drug-Eluting Stent Implantation Zhang-Wei Chen, MD; Ju-Ying
More informationAre We Making Progress With Percutaneous Saphenous Vein Graft Treatment? A Comparison of 1990 to 1994 and 1995 to 1998 Results
Journal of the American College of Cardiology Vol. 38, No. 1, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01324-9 Are We
More informationJournal of the American College of Cardiology Vol. 44, No. 9, by the American College of Cardiology Foundation ISSN /04/$30.
Journal of the American College of Cardiology Vol. 44, No. 9, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.05.085
More informationA Randomized Comparison of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin After the Placement of Coronary Artery Stents
Journal of the American College of Cardiology Vol. 41, No. 6, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02974-1
More informationInterventional Cardiology
Clinical Investigations Interventional Cardiology Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: Insights from the very early outcomes in the
More informationPeriprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion
Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol
More informationP ostprocedural creatine kinase and its MB isoform
1181 INTERVENTIONAL CARDIOLOGY AND SURGERY Prognostic role of cardiac troponin I after percutaneous coronary intervention in stable coronary disease T Nageh, R A Sherwood, B M Harris, M R Thomas... See
More informationAssociation Between CK-MB Elevation After Percutaneous or Surgical Revascularization and Three-Year Mortality
Journal of the American College of Cardiology Vol. 40, No. 11, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)02538-X
More informationThe beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome
International Journal of Cardiology 137 (2009) 246 251 www.elsevier.com/locate/ijcard The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with
More informationTHE ECONOMICS OF ADJUNCTIVE THERAPIES IN CORONARY ANGIOPLASTY: DRUGS, DEVICES, OR BOTH?
THE ECONOMICS OF ADJUNCTIVE THERAPIES IN CORONARY ANGIOPLASTY: DRUGS, DEVICES, OR BOTH? Paul I. Oh, 1 Eric A. Cohen, 2 Nicole Mittmann, 3, 4 Soo Jin Seung 4 1 Division of Clinical Pharmacology, Sunnybrook
More informationPlatelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes
European Heart Journal (00) 3, 1441 1448 doi:10.1053/euhj.00.3160, available online at http://www.idealibrary.com on Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes Gradient of benefit
More informationApproximately 1.5 million patients undergo percutaneous coronary
T h e n e w e ngl a nd j o u r na l o f m e dic i n e review article Current Concepts Myocardial Infarction Due to Percutaneous Coronary Intervention Abhiram Prasad, M.D., and Joerg Herrmann, M.D. Approximately
More informationCorrelates of Adverse Events During Saphenous Vein Graft Intervention With Distal Embolic Protection
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 1, NO. 2, 2008 2008 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/08/$34.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2008.01.002 Correlates
More informationContemporary Percutaneous Coronary Intervention Versus Balloon Angioplasty for Multivessel Coronary Artery Disease
Contemporary Percutaneous Coronary Intervention Versus Balloon Angioplasty for Multivessel Coronary Artery Disease A Comparison of the National Heart, Lung and Blood Institute Dynamic Registry and the
More informationJournal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL
More informationInfluence of Planned Six-Month Follow-Up Angiography on Late Outcome After Percutaneous Coronary Intervention A Randomized Study
Journal of the American College of Cardiology Vol. 38, No. 4, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01476-0 Influence
More informationA Pooled Analysis of Five Randomized Clinical Trials
Lack of Benefit From Intravenous latelet Glycoprotein IIb/IIIa Receptor Inhibition as Adjunctive Treatment for ercutaneous Interventions of Aortocoronary Bypass Grafts A ooled Analysis of Five Randomized
More informationPrognostic importance of troponin T and creatine kinase after elective angioplasty
International Journal of Cardiology 120 (2007) 242 247 www.elsevier.com/locate/ijcard Prognostic importance of troponin T and creatine kinase after elective angioplasty Mark B. Nienhuis a, Jan Paul Ottervanger
More informationCardiac Troponin I Levels and Clinical Outcomes in Patients With Acute Coronary Syndromes The Potential Role of Early Percutaneous Revascularization
Journal of the American College of Cardiology Vol. 34, No. 6, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00434-9 Cardiac
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationSeven-Year Outcome in the RITA-2 Trial: Coronary Angioplasty Versus Medical Therapy
Journal of the American College of Cardiology Vol. 42, No. 7, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00951-3
More informationNovel Risk Markers in ACS (Hyperglycemia, Anemia, GFR)
Novel Risk Markers in ACS (Hyperglycemia, Anemia, GFR) Shaul Atar, MD Department of Cardiology Faculty of Medicine of the Galilee Western Galilee Medical Center, Nahariya, Israel TIMI Risk Score Age 65
More informationPercutaneous coronary intervention (PCI), in
ECONOMIC IMPLICATIONS OF THE USE OF DIRECT THROMBIN INHIBITORS IN PERCUTANEOUS CORONARY INTERVENTION David J. Cohen, MD, MSc * ABSTRACT More than 1.2 million percutaneous coronary intervention (PCI) procedures
More informationPoint-of-Care Assessment of Platelet Reactivity After Clopidogrel to Predict Myonecrosis in Patients Undergoing Percutaneous Coronary Intervention
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 3, NO. 3, 2010 2010 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/10/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2009.12.012 Point-of-Care
More informationABOUT CORONARY ARtery
ORIGINAL CONTRIBUTION Association of Myocardial Enzyme Elevation and Survival Following Coronary Artery Bypass Graft Surgery Michael J. Domanski, MD Kenneth Mahaffey, MD Vic Hasselblad, PhD Sorin J. Brener,
More informationIndex. Note: Page numbers of article titles are in boldface type.
Cardiol Clin 24 (2006) 299 304 Index Note: Page numbers of article titles are in boldface type. A Abciximab in PCI, 180 182 ACE trial, 182 Actinomycin D-eluting stent, 224 ACUITY trial, 190 Acute myocardial
More informationCreatine kinase-mb (CK-MB) elevation after percutaneous
Prognostic Implications of Creatine Kinase-MB Elevation After Percutaneous Coronary Intervention Results From the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) Registry Jason B. Lindsey,
More informationJournal of the American College of Cardiology Vol. 37, No. 2, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01133-5 Coronary
More informationClopidogrel Date: 15 July 2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationInter-regional differences and outcome in unstable angina
European Heart Journal (2000) 21, 1433 1439 doi:10.1053/euhj.1999.1983, available online at http://www.idealibrary.com on Inter-regional differences and outcome in unstable angina Analysis of the International
More informationCardiovascular Disorders Lecture 3 Coronar Artery Diseases
Cardiovascular Disorders Lecture 3 Coronar Artery Diseases By Prof. El Sayed Abdel Fattah Eid Lecturer of Internal Medicine Delta University Coronary Heart Diseases It is the leading cause of death in
More informationJournal of the American College of Cardiology Vol. 41, No. 6, by the American College of Cardiology Foundation ISSN /03/$30.
Journal of the American College of Cardiology Vol. 41, No. 6, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02970-4
More informationCOURAGE to Leave Diseased Arteries Alone
COURAGE to Leave Diseased Arteries Alone Spencer King MD MACC, FSCAI St. Joseph s s Heart and Vascular Institute Professor of Medicine Emeritus Emory Univ. Atlanta, USA Conflict: I am an Interventionalist
More informationDefining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention
Defining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention Aggregate Results From 6 Randomized, Controlled Trials Derek P. Chew, MBBS; Deepak L. Bhatt, MD; A. Michael Lincoff,
More informationCase Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA
Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA Case History A 50-year-old man with type 1 diabetes mellitus and hypertension presents after experiencing 1 hour of midsternal chest pain that began after
More informationMyocardial necrosis has classically been detected by
Incidence, Predictors, and Significance of Abnormal Cardiac Enzyme Rise in Patients Treated With Bypass Surgery in the Arterial Revascularization Therapies Study (ARTS) Marco A. Costa, MD, PhD; Ronald
More informationInternational Journal of Collaborative Research on Internal Medicine & Public Health (IJCRIMPH)
Same-day discharge after percutaneous coronary intervention in light of the society for cardiovascular angiography and intervention's proposed guidelines: A single-center experience Yazan Khouri, Sachin
More informationJournal of the American College of Cardiology Vol. 35, No. 2, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 2, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00564-1 Procedural
More informationMethods The PARAGON-B trial
Misreporting of myocardial infarction end points: Results of adjudication by a central clinical events committee in the PARAGON-B trial Kenneth W. Mahaffey, MD, a Matthew T. Roe, MD, a Christopher K. Dyke,
More informationJournal of the American College of Cardiology Vol. 48, No. 11, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 11, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.12.084
More informationMETHODS OBJECTIVES BACKGROUND METHODS
Journal of the American College of Cardiology Vol. 36, No. 3, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00814-7 Platelet
More informationHealth technology Abciximab use in high-risk patients undergoing percutaneous transluminal coronary angioplasty.
Costs and effects in therapy for acute coronary syndromes: the case of abciximab in highrisk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study van Hout B A, Bowman L,
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationIn patients with acute coronary syndromes, the elevation. Prognostic Value of Troponin T after Elective Percutaneous Coronary Intervention
Original Article rognostic Value of Troponin T after Elective ercutaneous Coronary Intervention A Ghaemian 1, S Masoumi 1, RA Mohammadpour 2 1 Mazandaran Heart Center, 2 Department of Biostatistics, Mazandaran
More informationTreatment Strategies for the Prevention of Ischemic Complications in Patients Undergoing Percutaneous Coronary Intervention with Stent Placement
Treatment Strategies for the Prevention of Ischemic Complications in Patients Undergoing Percutaneous Coronary Intervention with Stent Placement Pharmaceutical Care Project Outcomes Literature Evaluation
More informationHigh-Dose Tirofiban Administered as Bolus-Only during Percutaneous Coronary Intervention
Original Contribution High-Dose Tirofiban Administered as Bolus-Only during Percutaneous Coronary Intervention Jonathan D. Marmur, MD, Shyam Poludasu, MD, Ajay Agarwal, MD, Nagarathna Manjappa MD, Erdal
More informationTreatment of Saphenous Vein Bypass Grafts With Ultrasound Thrombolysis. A Randomized Study (ATLAS)
Treatment of Saphenous Vein Bypass Grafts With Ultrasound Thrombolysis A Randomized Study (ATLAS) Mandeep Singh, MD; Uri Rosenschein, MD; Kalon K.L. Ho, MD; Peter B. Berger, MD; Richard Kuntz, MD; David
More informationIschemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Phy
Ischemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Physician, Professor of Medicine Department of Cardiology,
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationJournal of the American College of Cardiology Vol. 40, No. 6, by the American College of Cardiology Foundation ISSN /02/$22.
Journal of the American College of Cardiology Vol. 40, No. 6, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)02119-8
More informationAcute coronary syndromes
Acute coronary syndromes 1 Acute coronary syndromes Acute coronary syndromes results primarily from diminished myocardial blood flow secondary to an occlusive or partially occlusive coronary artery thrombus.
More informationAcute Myocardial Infarction
Acute Myocardial Infarction Hafeza Shaikh, DO, FACC, RPVI Lourdes Cardiology Services Asst.Program Director, Cardiology Fellowship Associate Professor, ROWAN-SOM Acute Myocardial Infarction Definition:
More informationJournal of the American College of Cardiology Vol. 46, No. 8, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 46, No. 8, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.06.070
More informationPathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL
Pathology of percutaneous interventions (PCI) in coronary arteries Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL Percutaneous Coronary Intervention (PCI) Definition: transcatheter opening of
More informationGender-Based Outcomes in Percutaneous Coronary Intervention with Drug-Eluting Stents (from the National Heart, Lung, and Blood Institute Dynamic
Gender-Based Outcomes in Percutaneous Coronary Intervention with Drug-Eluting Stents (from the National Heart, Lung, and Blood Institute Dynamic Registry) J. D. Abbott, et al. Am J Cardiol (2007) 99;626-31
More informationAn update on the management of UA / NSTEMI. Michael H. Crawford, MD
An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB
More informationCost-efficacy in interventional cardiology
European Heart Journal (21) 22, 1476 1484 doi:1.153/euhj.2.43, available online at http://www.idealibrary.com on Cost-efficacy in interventional cardiology Results from the EPISTENT study J. E. F. Zwart-van
More informationPost-Procedural Myocardial Injury or Infarction
Post-Procedural Myocardial Injury or Infarction Hugo A Katus MD & Evangelos Giannitsis MD Abteilung Innere Medizin III Kardiologie, Angiologie, Pulmologie Universitätsklinikum Heidelberg Conflict of Interest:
More informationImpact of Body Mass Index on Long-Term All-Cause Mortality after Percutaneous Coronary Intervention in African-Americans
Original Contribution Impact of Body Mass Index on Long-Term All-Cause Mortality after Percutaneous Coronary Intervention in African-Americans Shyam Poludasu, MD, Erdal Cavusoglu, MD, Waqas Khan, MD, Jonathan
More informationAtherosclerotic Plaque Burden and CK-MB Enzyme Elevation After Coronary Interventions. Intravascular Ultrasound Study of 2256 Patients
Atherosclerotic Plaque Burden and CK-MB Enzyme Elevation After Coronary Interventions Intravascular Ultrasound Study of 2256 Patients Roxana Mehran, MD; George Dangas, MD, PhD; Gary S. Mintz, MD; Alexandra
More informationThe risk of death or ischemic events in patients with
Prediction of Outcome after Percutaneous Coronary Intervention for the Acute Coronary Syndrome Annapoorna S. Kini, MD, Paul C. Lee, MD, Cristina A. Mitre, MD, Michael C. Kim, MD, Mazullah Kamran, MD, Mary
More informationJAMA. 2004;292:
ORIGINAL CONTRIBUTION Long-term Efficacy of and Provisional Blockade vs Heparin and Planned Blockade During Percutaneous Coronary Revascularization REPLACE-2 Randomized Trial A. Michael Lincoff, MD Neal
More informationThe Effects of Aspirin and Clopidogrel Response on Myonecrosis After Percutaneous Coronary Intervention
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 1, NO. 6, 2008 2008 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/08/$34.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2008.08.017 The Effects
More informationSafety and Efficacy of Angioplasty with Intracoronary Stenting in Patients with Unstable Coronary Syndromes. Comparison with Stable Coronary Syndromes
Original Article Safety and Efficacy of Angioplasty with Intracoronary Stenting in Patients with Unstable Coronary Syndromes. Comparison with Stable Coronary Syndromes Luís C. L. Correia, José Carlos Brito,
More informationAcute Myocardial Infarction. Willis E. Godin D.O., FACC
Acute Myocardial Infarction Willis E. Godin D.O., FACC Acute Myocardial Infarction Definition: Decreased delivery of oxygen and nutrients to the myocardium Myocardial tissue necrosis causing irreparable
More informationHorizon Scanning Centre November 2012
Horizon Scanning Centre November 2012 Cangrelor to reduce platelet aggregation and thrombosis in patients undergoing percutaneous coronary intervention99 SUMMARY NIHR HSC ID: 2424 This briefing is based
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial
ARMYDA-RECAPTURE ( for Reduction of MYocardial Damage during Angioplasty) trial Prospective, multicenter, randomized, double blind trial investigating efficacy of atorvastatin reload in patients on chronic
More informationEmbolization of atherothrombotic debris occurs commonly
Randomized Comparison of Distal Protection With a Filter-Based Catheter and a Balloon Occlusion and Aspiration System During Percutaneous Intervention of Diseased Saphenous Vein Aorto-Coronary Bypass Grafts
More informationClinical research Interventional cardiology
European Heart Journal (2006) 27, 920 928 doi:10.1093/eurheartj/ehi736 Clinical research Interventional cardiology Platelet glycoprotein receptor inhibition as adjunctive treatment during saphenous vein
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationImpact of Gender on In-Hospital Percutaneous Coronary Interventional Outcomes in African-Americans
Original Contribution Impact of Gender on In-Hospital Percutaneous Coronary Interventional Outcomes in African-Americans Shyam Poludasu, MD, Erdal Cavusoglu, MD, Luther T. Clark, MD, Jonathan D. Marmur,
More informationPost Operative Troponin Leak: David Smyth Christchurch New Zealand
Post Operative Troponin Leak: Does It Really Matter? David Smyth Christchurch New Zealand Life Was Simple Once Transmural Infarction Subendocardial Infarction But the Blood Tests Were n t Perfect Creatine
More informationOUTCOMES WITH LONGTERM DUAL ANTIPLATELET THERAPY AFTER CORONARY ANGIOPLASTY Ashok Kumar Arigonda, K. Nagendra Prasad, O. Hareesh, R.
INDIAN JOURNAL OF CARDIOVACULAR DIEAE JOURNAL in women (IJCD) 016 VOL 1 IUE 3 ORIGINAL ARTICLE 1 OUTCOME WITH LONGTERM DUAL ANTIPLATELET THERAPY AFTER CORONARY ANGIOPLATY Ashok Kumar Arigonda, K. Nagendra
More informationOutcomes With the Paclitaxel-Eluting Stent in Patients With Acute Coronary Syndromes Analysis From the TAXUS-IV Trial
Journal of the American College of Cardiology Vol. 45, No. 8, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.10.074
More informationIncremental Prognostic Value of Elevated Baseline C-Reactive Protein Among Established Markers of Risk in Percutaneous Coronary Intervention
Incremental Prognostic Value of Elevated Baseline C-Reactive Protein Among Established Markers of Risk in Percutaneous Coronary Intervention Derek P. Chew, MBBS; Deepak L. Bhatt, MD; Mark A. Robbins, MD;
More informationCoronary Plaque Sealing: The DEFER Study and more...
Coronary Plaque Sealing: The DEFER Study and more... How Waiting Can Be Beneficial in Stable Coronary Artery Disease Patients ESC, Stockholm, 2005 M. Romanens, 21.09.2005 at www.kardiolab.ch DEFER Study:
More information1. Prevalence and prognostic significance of incidental cardiac troponin T elevation in ambulatory patients with stable coronary artery disease: data from the Heart and Soul study Hsieh, B.P., et al. Am
More informationORIGINAL INVESTIGATION. Troponin Criteria for Myocardial Infarction After Percutaneous Coronary Intervention
ONLINE FIRST ORIGINAL INVESTIGATION Troponin Criteria for Myocardial Infarction After Percutaneous Coronary Intervention Victor Novack, MD, PhD; Michael Pencina, PhD; David J. Cohen, MD, MSc; Neal S. Kleiman,
More informationImpact of Clinical Syndrome Acuity on the Differential Response to 2 Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Coronary Stenting
Impact of Clinical Syndrome Acuity on the Differential Response to 2 Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Coronary Stenting The TARGET Trial* Gregg W. Stone, MD; David J. Moliterno,
More informationPrimary PCI versus thrombolytic therapy: long-term follow-up according to infarct location
Heart Online First, published on April 14, 2005 as 10.1136/hrt.2005.060152 1 Primary PCI versus thrombolytic therapy: long-term follow-up according to infarct location Short running head: Anterior infarction
More informationCLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA
RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA Dr Lincoff is an interventional cardiologist and the Vice Chairman for Research
More informationCase Report Rheolytic Thrombectomy Combined with a Protective Filter and Platelet Glycoprotein IIb/IIIa Receptor Inhibitors in Rescue Angioplasty
Hell J Cardiol 46: 430-434, 2005 Case Report Rheolytic Thrombectomy Combined with a Protective Filter and Platelet Glycoprotein IIb/IIIa Receptor Inhibitors in Rescue Angioplasty PETROS S. DARDAS, NIKOS
More informationCulprit PCI vs MultiVessel PCI for Acute Myocardial Infarction
Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction Dipti Itchhaporia, MD, FACC, FESC Trustee, American College of Cardiology Director of Disease Management, Hoag Hospital Robert and Georgia
More informationA Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in Patients with Non-ST Elevation ACS
Angioplasty to Blunt the rise Of troponin in Acute coronary syndromes Randomized for an immediate or Delayed intervention A Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in
More informationCardiovascular risk and therapeutic benefit of coronary interventions for patients with unstable angina according to the troponin T status
European Heart Journal (2000) 21, 1159 1166 doi:10.1053/euhj.1999.1986, available online at http://www.idealibrary.com on Cardiovascular risk and therapeutic benefit of coronary interventions for patients
More informationLoading Dose of Rosuvastatin Before PCI and its Beneficial Post-Procedural Effects: A Systematic Review
Pacific University CommonKnowledge School of Physician Assistant Studies Theses, Dissertations and Capstone Projects Summer 8-9-2014 Loading Dose of Rosuvastatin Before PCI and its Beneficial Post-Procedural
More informationPrognostic Significance of Epicardial Blood Flow Before and After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes
Journal of the American College of Cardiology Vol. 52, No. 7, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.05.009
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationJournal of the American College of Cardiology Vol. 45, No. 9, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 45, No. 9, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.01.030
More informationJournal of the American College of Cardiology Vol. 36, No. 2, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 36, No. 2, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00752-X A Comparison
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationVCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital
VCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital Complex PCI: Multivessel Disease George W. Vetrovec, MD. Kimmerling Chair of Cardiology VCU Pauley Heart Center Virginia
More information